ConductScience.org, home

Paper40960239

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

Wharton S and 13 others. N Engl J Med, 2025. Cited by 115 papers, by iCite.

Cite this record

ConductScience Library. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. Papers, record 40960239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40960239

Download JSON
Disease
obesity disorder354 drugs
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.
PubMed
Journal
N Engl J Med
PubMed
Year
2025
PubMed
Publication types
Journal Article, Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase III
PubMed
Citations, by iCite
115
iCite
Relative citation ratio, by iCite
32.08, provisional
iCite
Revised in PubMed
2025-11-17
PubMed

Authors14

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wharton SSean
2Aronne LJLouis J
3Stefanski AAdam
4Alfaris NFNasreen F
5Ciudin AAndreea
6Yokote KKoutaro
7Halpern BBrunohttps://orcid.org/0000-0003-0973-5065
8Shukla APAlpana P
9Zhou CChunmei
10Macpherson LLisa
11Allen SESheryl E
12Ahmad NNNadia N
13Klise SRSuzanne R
14ATTAIN-1 Trial InvestigatorsGroup

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Anti-Obesity AgentsMajor topic
Glucagon-Like Peptide-1 Receptor AgonistsMajor topic
ObesityMajor topic
Weight LossMajor topic
Adult
Female
Humans
Male
Middle Aged
Administration, Oral
Double-Blind Method
Intention to Treat Analysis
Gastrointestinal Diseases
Fluorine Compounds
Oxadiazoles
Treatment Outcome

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT05869903A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related ComorbiditiesDerived from the trialYes

Source ClinicalTrials.gov

Download CSV of trials

Cited by92

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 115 citations.

PMIDTitleJournalYearIn PapersSource
42983568Reported cardiovascular events and cardiometabolic risk markers with orforglipron and danuglipron in adults with type 2 diabetes or obesity: a systematic review and meta-analysis of randomized trials.Diabetol Metab Syndr2026https://conductscience.org/library/papers/42983568PubMed
42978695Diabesity: an old term, a modern challenge - multi-omics and precision anti-obesity pharmacotherapy in type 2 diabetes.J Pharm Pharm Sci2026https://conductscience.org/library/papers/42978695PubMed
42977781[New oral anti-obesity drugs: the future or second choice?]Inn Med (Heidelb)2026https://conductscience.org/library/papers/42977781PubMed
42942813Progress in Anti-Obesity Drug Development: A Pharmacodynamics Perspective.Pharmaceutics2026https://conductscience.org/library/papers/42942813PubMed
42942810Retatrutide as a Unimolecular GIP/GLP-1/Glucagon Receptor Tri-Agonist: Molecular Design, Pharmaceutical Development and Critical Interpretation of Emerging Phase 3 Evidence.Pharmaceutics2026https://conductscience.org/library/papers/42942810PubMed
42936354Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial.Obes Pillars2026https://conductscience.org/library/papers/42936354PubMed
42936006Estimating the Health, Economic, and Social Benefits of Obesity Treatment Using Microsimulation Modeling.Diabetes Obes Cardiometab CARE2026https://conductscience.org/library/papers/42936006PubMed
42889249Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.Cureus2026https://conductscience.org/library/papers/42889249PubMed
42871841Oral Obesity Medicines in the Era of Cardiovascular-Kidney-Metabolic Syndrome (CKM): Beyond Weight Loss Toward Disease Modification.Drug Des Devel Ther2026https://conductscience.org/library/papers/42871841PubMed
42851902Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42851902PubMed
42830762Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension.Am J Prev Cardiol2026https://conductscience.org/library/papers/42830762PubMed
42808923Gastrointestinal adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 receptor agonists: A narrative expert review of approved therapies, oral formulations, and pipeline agents.Nutr Clin Pract2026https://conductscience.org/library/papers/42808923PubMed
42783450The Possible Hematological Cost of Metabolic Success: Do Incretin-Based Therapies Silently Trigger Anemia?Med Sci (Basel)2026https://conductscience.org/library/papers/42783450PubMed
42769318Advances in the management of obesity: non-pharmacological strategies, herbal formulations, current pharmacotherapy, emerging drugs, and future perspectives.Front Endocrinol (Lausanne)2026https://conductscience.org/library/papers/42769318PubMed
42755136Preferences for Obesity Medications Among People With Overweight or Obesity in the United States: A Discrete-Choice Experiment (OPTIC).Diabetes Obes Metab2026https://conductscience.org/library/papers/42755136PubMed
42751234Redefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists.World J Transplant2026https://conductscience.org/library/papers/42751234PubMed
42750540Predicting the Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease With Orforglipron in People With Overweight or Obesity: A Post Hoc Analysis of the ATTAIN-1 Trial.Diabetes Obes Metab2026https://conductscience.org/library/papers/42750540PubMed
42750018Efficacy and safety of orforglipron 12 mg versus orforglipron 36 mg maintenance dose among patients with obesity with or without diabetes: a systematic review and comprehensive meta-analysis.BMC Endocr Disord2026https://conductscience.org/library/papers/42750018PubMed
42713454Glucagon-Like Peptide-1 Receptor Agonist Use Before and After Liver Transplant.Gastroenterol Hepatol (N Y)2026https://conductscience.org/library/papers/42713454PubMed
42712498Cardiometabolic drugs after stroke: time to embrace SGLT2 inhibitors and incretin-based therapies?Front Stroke2026https://conductscience.org/library/papers/42712498PubMed

See all 92 cited byDownload CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740

Source NCBI Gene

Download CSV of genes

Drugs1

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targets
ORFORGLIPRONCHEMBL4446782Derived from the trial1https://conductscience.org/library/drugs/CHEMBL4446782

Source ChEMBL

Download CSV of drugs

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • References
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40960239

GET https://conductscience.org/api/papers/v1/40960239/cited_by?page=2